Abstract:Background: Metastasis-associated protein 2 (MTA2) is a member of the metastasis-associated transcriptional regulator family and is a core component of the nucleosome remodeling and histone deacetylation complex. Despite growing evidence that MTA2 plays a crucial role in the tumorigenesis of certain cancers, no systematic pan-cancer analysis of MTA2 is available to date. Therefore, the aim of our study is to explore the prognostic value of MTA2 in 33 cancer types and to investigate its potential immune function. Methods: by comprehensive use of databases from TCGA, GTEx, GEO, UCSC xena, cBioPortal, comPPI, GeneMANIA, TCIA, MSigDB, and PDB, we applied various bioinformatics approaches to investigate the potential role of MTA2, including analyzing the association of MTA2 with MSI, prognosis, gene mutation, and immune cell infiltration in different tumors. We constructed a nomogram in TCGA-LIHC, performed single-cell sequencing (scRNA-seq) analysis of MTA2 in hepatocellular carcinoma (HCC), and screened drugs for the treatment of HCC. Finally, immunohistochemical experiments were performed to verify the expression and prognostic value of MTA2 in HCC. In vitro experiments were employed to observe the growth inhibition effects of MK-886 on the HCC cell line HepG2. Results: The results suggested that MTA2 was highly expressed in most cancers, and MTA2 expression was associated with the prognosis of different cancers. In addition, MTA2 expression was associated with Tumor Mutation Burden (TMB) in 12 cancer types and MSI in 8 cancer types. Immunoassays indicated that MTA2 positively correlated with activated memory CD4 T cells and M0 macrophage infiltration levels in HCC. ScRNA-seq analysis based on the GEO dataset discovered that MTA2 was significantly expressed in T cells in HCC. Finally, the eXtreme Sum (Xsum) algorithm was used to screen the antitumor drug MK-886, and the molecular docking technique was utilized to reveal the binding capacity between MK-886 and the MTA2 protein. The results demonstrated excellent binding sites between them, which bind to each other through Π-alkyl and alkyl interaction forces. An immunohistochemistry experiment showed that MTA2 protein was highly expressed in HCC, and high MTA2 expression was associated with poor survival in HCC patients. MK-886 significantly inhibited the proliferation and induced cell death of HepG2 cells in a dose-dependent manner. Conclusions: Our study demonstrated that MTA2 plays crucial roles in tumor progression and tumor immunity, and it could be used as a prognostic marker for various malignancies. MK-886 might be a powerful drug for HCC.

Expressions and relationship between MTA1 and MMP-2 in hepetocellular carcinoma tissues

Expressions and clinical significance of CD146 and MMP-2 in hepatocellular carcinoma

The expression of tumor metastasis suppressor gene KAI1 and matrix metalloproteinase 2 in breast cancer tissues

Relationship of HDGF or VEGF expression with hepatocellular carcinoma angiogenesis:report of 108 cases

Expression of extracellular matrix metalloproteinase inducer CD147 and MMP-9 in hepatocellular carcinoma and its clinical significance

Expression of MTA3 in Hepatocellular Carcinoma and Its Significance

Expression and Clinical Significance of RECK and MMP-14 in Hepatocellular Carcinoma

Correlation of MCP-1 Expression with Angiogenesis in Hepatocellular Carcinoma

Expression and Clinical Significance of CD146 and VEGF in Hepatocellular Carcinoma

Relationship of MMP-2mRNA Expression with Clinical Pathological Features and Prognosis in Gastric Cancer

Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma

Expression of MTA1 Protein in Non-Small Cell Lung Cancer and Its Association with the Prognosis of the Disease

The Role of Matrix Metalloproteinase Expression in Lung Cancer Metastasis

Elevated MTSS1 Expression Associated with Metastasis and Poor Prognosis of Residual Hepatitis B-related Hepatocellular Carcinoma

Metallothionein 1h Functions As A Tumor Suppressor in Hepatocellular Carcinoma

Expression and clinical significance of metadherin in hepatocellular carcinoma

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

Expression and Significance of Metastasis-Associated Gene 1(MTA1), Vascular Endothelial Growth Factor C(VEGF-C)in Non-Small Cell Lung Cancer Using Tissue Microarray

Expression of Cytokeratin 19 and Matrix Metalloproteinase 2 Predicts Lymph Node Metastasis in Hepatocellular Carcinoma.

Expression of HIF-1α and VEGF in Hepatocellular Carcinoma and Correlation with Tumor Angiogenesis

Expression of MMP-9 Mrna in Human Hepatocellular Carcinoma